Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.
Also called NCT02770261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 219 participants
- Sponsor
- Alvogen Korea
- Registry
-
NCT02770261
-
- Other papers using this trial's data
- Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT02770261. Randomized; double masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
- Condition
- Hypertension
- Condition
- Cholesterolemia
- Intervention (Drug)
- DP-R208
- Intervention (Drug)
- Candesartan32mg
- Intervention (Drug)
- Rosuvastatin 20mg
- Intervention (Drug)
- DP-R208 Placebo
- Intervention (Drug)
- Candesartan32mg Placebo
- Intervention (Drug)
- Rosuvastatin 20mg Placebo
- Lead sponsor
- Alvogen Korea
Record details
- Record id
cardio:ct-nct02770261- Content hash
830756300f03c106f2268ea26384866f46f2bb55fa5bf9b19052b97ca8a968c1